Trial Profile
A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms DESCARTES; PROFICIO
- Sponsors Amgen
- 08 Nov 2017 Results (n=619) of post hoc analysis evaluating the effect of evolocumab on lipoprotein particle concentrations published in the American Journal of Cardiology
- 01 Mar 2017 Results (n=6026) of pooled safety analysis of this and other eleven trials (LAPLACE-TIMI 57,RUTHERFORD,GAUSS,MENDEL,YUKAWA,LAPLACE-2,RUTHERFORD-2,GAUSS-2,MENDEL-2,DISCARTES,THOMAS-1,THOMAS-2) published in the Circulation.
- 16 Nov 2016 Results of post hoc analysis assessing the effect of evolocumab on lipoprotein particle concentrations in patients with and without diabetes, presented at the 89th Annual Scientific Sessions of the American Heart Association